The drug effectiveness review project: an important step forward.
Peter Neumann's paper on the Drug Effectiveness Review Project (DERP) is a constructive if incomplete point of departure for discussing the work done by the project and the use of that work by decision-makers in states and elsewhere. This Perspective attempts to establish the proper context for judging the DERP by comparing its product and processes with those commonly produced and used by industry and other parties. It also provides a direct response to the criticisms of the project noted by Neumann.
Gibson
Mark
M
Center for Evidence-based Policy, Oregon Health and Science University, Portland, USA. gibsomar@ohsu.edu
Santa
John
J
D003362:Cost-Benefit Analysis; D003657:Decision Making; D017723:Drug Utilization Review / Q000191:economics / Q000379:methods*; D017598:Efficiency, Organizational; D019317:Evidence-Based Medicine; D005569:Formularies as Topic; D006265:Health Care Coalitions; D006801:Humans